SOURCE: Lipid Sciences, Inc.

July 15, 2005 10:00 ET

H. Bryan Brewer, Jr., M.D., Lipid Sciences' Chief Scientific Director Delivers Plenary Session Presentation at International Symposium on Triglycerides and HDL: Role in Cardiovascular Disease and

the Metabolic Syndrome

PLEASANTON, CA -- (MARKET WIRE) -- July 15, 2005 -- Lipid Sciences, Inc. (NASDAQ: LIPD) announced today that H. Bryan Brewer, Jr., M.D., Lipid Sciences' Vice Chairman, Chief Scientific Director and Chairman of the Company's Scientific Advisory Board made an invited Plenary Session presentation today at the International Symposium on Triglycerides and HDL: Role in Cardiovascular Disease and the Metabolic Syndrome, sponsored by the Giovanna Lorenzini Medical Foundation. Dr. Brewer's presentation at the New York Marriott Marquis in New York City was titled "Increasing HDL as an Emerging Approach to the Treatment of CVD." In addition, Frank M. Sacks, M.D., Professor of Cardiovascular Disease Prevention, Harvard School of Public Health, a member of Lipid Sciences' Scientific Advisory Board, moderated a workshop at the Symposium.

Lipid Sciences' Chairman of the Board, Richard G. Babbitt commented, "We are very pleased that Lipid Sciences' scientific advisors, such as Dr. Brewer and Dr. Sacks are at the very forefront of scientific developments in assessing the opportunities represented by HDL as a promising therapeutic target in the treatment of cardiovascular disease. We look to our subject matter experts to help us create a roadmap for our strategic initiatives and investment surrounding HDL therapy."

For further information about Lipid Sciences' selective delipidation technology, please visit the Company's website:

Lipid Sciences, Inc. is a development-stage biotechnology company engaged in the research and development of products and processes intended to treat major medical indications, in which lipids, or fat components, play a key role. The Company's technologies are based on a unique patented process, known as delipidation, which selectively and rapidly removes lipids, such as cholesterol, from targeted lipoproteins or viruses circulating in blood plasma without disrupting the non-targeted plasma protein function. The Company's HDL Therapy Platform is aimed at developing treatments for the reversal of atherosclerosis, a systemic disease of the blood vessels caused by the build-up of cholesterol-filled plaques in the vascular system and, most critically, in the coronary arteries. If left untreated, these plaques are highly vulnerable to rupture and to blood clot formation, which can result in a fatal myocardial infarction (heart attack). Regression of such plaques may have a major impact on reducing the risk of acute coronary events. The Company's Viral Immunotherapy Platform is focused on the removal of the lipid coatings from lipid-enveloped viruses and other lipid-containing infectious agents by application of Lipid Sciences' delipidation technology. The Company believes that removing the virus' protective lipid coating exposes otherwise hidden viral proteins, to stimulate the body's immune system to effectively fight the disease. Conditions that could potentially be impacted by this technology include HIV, Hepatitis B and Hepatitis C, West Nile, SARS and influenza.

Forward-Looking Statements: This release contains forward-looking statements concerning plans, objectives, goals, strategies, study results, anticipations, expectations, future events or performance as well as all other statements that are not statements of historical fact. The forward-looking statements contained in this release reflect our current beliefs and expectations on the date of this release. Actual results, performance or outcomes may differ materially from what is expressed in the forward-looking statements. Readers are referred to the documents filed by us with the SEC, specifically the most recent reports on Form 10-K and Form 10-Q which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. In addition to those risk factors, other factors that could cause actual results to differ materially include the following: Our inability to obtain adequate funds; our technology not proving to be safe or effective; our inability to obtain regulatory approval for our technology, which is only in the clinical development stage; delay or failure to complete clinical studies; our dependence on our license agreement with Aruba International B.V.; our reliance on collaborations with strategic partners and consultants; competition in our industry, including the development of new products by others that may provide alternative or better therapies; failure to secure and enforce our intellectual property rights; risks associated with use of biological and hazardous materials; and our dependence on key personnel.

This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q. Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at Lipid Sciences assumes no obligation to update the forward-looking statements included in this document.

Press releases for Lipid Sciences, Inc. are available on our website: If you would like to receive our press releases via email, please contact:

Contact Information


    Deborah S. Lorenz
    Vice President, Investor Relations and
    Corporate Communications
    Lipid Sciences, Inc.
    Email Contact

    Donald C. Weinberger
    Wolfe Axelrod Weinberger Associates, LLC
    Email Contact